Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03025308 · ClinicalTrials.gov registry record · Phase 3
Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis
A Phase 3 study, sponsored by Alfasigma S.p.A..
- Completed
- Registry status
- Phase 3
- Development phase
- 2,731
- Enrollment target
NCT03025308 is a Phase 3 study that has completed, run by Alfasigma S.p.A.. The registered enrollment target is 2,731 participants.
The verdict
NCT03025308, a Phase 3 study, has completed, sponsored by Alfasigma S.p.A..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,731 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of filgotinib in participants who have completed one of the parent studies of filgotinib in rheumatoid arthritis (RA).
Interventions
- DRUG Filgotinib
- DRUG Placebo to match filgotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,731 participants |
| Start Date | 2017-02-28 |
| Est. Completion | 2025-05-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03025308
The ClinicalTrials.gov registry entry for NCT03025308 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,731 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alfasigma S.p.A., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Filgotinib is the first listed.
NCT03025308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03025308 about?
NCT03025308 is a clinical study titled "Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis". The primary objective of this study is to evaluate the long-term safety and tolerability of filgotinib in participants who have completed one of the parent studies of filgotinib in rheumatoid arthritis (RA).
What is the current status of trial NCT03025308?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,731 participants. The study started on 2017-02-28. Estimated completion is 2025-05-16.
What interventions are being tested in trial NCT03025308?
The interventions under investigation include: Filgotinib (DRUG), Placebo to match filgotinib (DRUG).
Who is sponsoring clinical trial NCT03025308?
This trial is sponsored by Alfasigma S.p.A., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.